No Data
No Data
Lexeo Stock Drops 24% Amid Friedreich Ataxia Study Results
We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success
Larimar Stock Rallies 24% on FDA Removal of Partial Clinical Hold
Design Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic Review
Hold Rating Maintained for Design Therapeutics Amid Strategic Updates and Financial Review
RBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)